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     Fluoroquinolone antimicrobial drugs are efficiently absorbed after oral administration 
despite of their hydrophilicity, implying an involvement of carrier-mediated transport in their 
membrane transport process.  We have shown that several fluoroquinolones are substrates of 
organic anion transporter polypeptides OATP1A2 expressed in human intestine derived Caco-2 
cells.  In the present study, to clarify the involvement of OATP in intestinal absorption of 
ciprofloxacin, we investigated a contribution of Oatp1a5, which is expressed at the apical 
membranes of rat enterocytes, to intestinal absorption of ciprofloxacin in rats.  Intestinal 
membrane permeability of ciprofloxacin was measured by in situ and vascular perfused closed 
loop method.  Disappearance and absorbed amount of ciprofloxacin from the intestinal lumen 
were markedly increased in the presence of 7,8-benzoflavone, a breast cancer resistance protein 
inhibitor, and ivermectin, a P-glycoprotein inhibitor, while it was significantly decreased in the 
presence of these inhibitors in combination with naringin, an Oatp1a5 inhibitor.  Furthermore, 
The Oatp1a5-mediated uptake of ciprofloxacin was saturable with Km value of 140 M, and 
naringin inhibited the uptake with IC50 value of 18 M by Xenopus oocytes expressing Oatp1a5.  
Naringin reduced the permeation of ciprofloxacin from mucosal-to-serosal side, with IC50 value 
of 7.5 M by Ussing-type chamber method.  The estimated IC50 values were comparable.  
These data suggested that Oatp1a5 was partially responsible for the intestinal absorption of 
ciprofloxacin.  In conclusion, intestinal absorption of ciprofloxacin could be affected by influx 
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transporters, such as Oatp1a5 as well as the efflux transporters such as P-gp and Bcrp. 
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     Fluoroquinolones are antimicrobial drugs in clinical use, which are effective for treatment 
of a wide range of bacterial and fungal infections.  Since most of fluoroquinolones are orally 
administrated to patients, their bioavailability is an important determinant for their 
pharmacological activity.  Early pharmacokinetic research has shown that some 
fluoroquinolones are efficiently absorbed from small intestines despite their hydrophilicity [1].  
For example, the bioavailability of ciprofloxacin was reported to be 63-84% [1,2].  Relatively 
high intestinal absorption might be explained by an involvement of carrier-mediated transport of 
ciprofloxacin across intestinal epithelial cells.  Indeed, previous reports have suggested that 
fluoroquinolones including ciprofloxacin are transported by several classes of membrane 
transporters; organic anion transporter 3 (OAT3/SLC22A8) [3], and efflux pumps such as 
p-glycoprotein (P-gp/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) [4-7].  Our 
recent study has shown that ciprofloxacin and levofloxacin can be transported by organic anion 
transporting polypeptide 1A2 (OATP1A2/SLCO1A2) in the human intestinal model Caco-2 cells 
and Xenopus oocytes expressing OATP1A2 [8]. 
     OATP1A2 is a solute carrier transporter that belongs to OATP/SLCO family, and functions 
as an influx transporter for a wide variety of anionic compounds in a Na+ independent manner [9, 
10].  Since OATP1A2 is expressed in brain, liver, and to a lesser extent kidney, testis and 
intestines [9,11], it likely contributes to pharmacokinetics of drugs.  In intestine, OATP/Oatp 
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molecules including OATP1A2 contribute to intestinal absorption of several drugs [12-18].  In 
addition to OATP1A2, apically-expressed OATP2B1 in intestinal epithelial cells has been also 
extensively studied and shown to be involved in the intestinal absorption of various compounds 
such as fexofenadine and pravastatin [11,19].  More importantly, clinical studies indicated that 
these intestinal OATPs are putative sites for drug-fruit juice (e.g. grapefruit, orange and apple 
juices) interactions, resulting in alteration of pharmacokinetics of their substrate drugs such as 
atenolol, celiprolol, fexofenadine and talinolol [20-26].  When ciprofloxacin was orally 
administered with orange juice, a significant decrease of its bioavailability was observed [27].  
These observations indicate that intestinal absorption of ciprofloxacin is mediated by membrane 
transporters such as OATPs, while the absorption mechanism is poorly understood.   
     In the present study, to clarify a mechanism of intestinal absorption of ciprofloxacin, we 
studied whether the drug is transported by rat Oatp1a5 (Slco1a5) or not and evaluated effect of 
naringin, which is a OATP/Oatp inhibitor in the constituent of grapefruit juice [28], since 
Oatp1a5 is expressed at the apical membranes of rat small intestinal epithelial cells [29] and has 
been the most extensively studied as the rat intestinal uptake transporter [30-32].  We present 
here Oatp1a5 at least plays a role in intestinal absorption of ciprofloxacin by means of in situ and 
in vitro rat intestinal membrane permeation method and Xenopus oocytes expressing Oatp1a5, 








     Ciprofloxacin, naringin, 7,8-benzoflavone, ivermectin and [3H]estrone-3-sulfate, 
ammonium salt (1702 GBq/mmol) were purchased from Tokyo Chemical Industry (Tokyo, 
Japan), Kanto Chemical (Tokyo, Japan), Wako Pure Chemical Industries (Osaka, Japan), 
Sigma-Aldrich (St. Louis, MO), and PerkinElmer Inc.  (Boston, MA), respectively.  All other 
compounds and reagents were obtained from Nakalai Tesque (Kyoto, Japan), Wako Pure 
Chemical Industries (Osaka, Japan) and Sigma-Aldrich (St. Louis, MO). 
 
Uptake experiments using Xenopus laevis oocyte 
 
     The coding region of Oatp1a5 gene was in vitro transcribed using mMESSAGE 
mMACHINE kit (Ambion, Austin, TX), and then a 50 nL of RNA solution containing 25 ng of 
transcribed RNA was directly injected to defoliculated Xenopus oocytes.  In general, uptake 
experiment was conducted as previously described [33].  Briefly, injected oocytes were placed 
for 3 days in modified Barth’s solution (MBS, 88 mM NaCl, 1.0 mM KCl, 2.4 mM NaHCO3, 
0.82 mM MgSO4, 0.33 mM Ca(NO3)2, 0.41 mM CaCl2 and 10 mM HEPES adjusted to pH 7.4 
with NaOH) at 18ºC, and then used for uptake experiments.  Uptake of ciprofloxacin (20 M) 
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was measured at room temperature in the MBS at pH 7.4.  Uptake was terminated by the 
addition of ice-cold MBS.  Oocytes were washed 3 times with ice-cold MBS. 
  Uptake results were shown by cell-to-medium ratio (microliters per oocyte), which was 
obtained by dividing the cellular uptake amount by the initial concentration of test compound in 
the uptake medium.  Cell-to-medium ratio represents the volume of cleared extracellular 
transport medium.  Oatp1a5-mediated uptake rate was obtained by subtracting the uptake of 
water-injected oocytes from that of Oatp1a5 cRNA-injected oocytes.  For inhibition study, 2, 5, 
10, 20 and 50 M of naringin were used. Kinetic parameters were established by means of 
nonlinear least-squares analysis using Kaleida Graph (Synergy Software, Reading, PA).  The 
Michaelis-Menten constant (Km) of ciprofloxacin uptake mediated by Oatp1a5 and its maximal 
velocity (Vmax) were obtained by fitting raw data to the following equation (1): 
 
v = Vmax × C/(Km + C)  (1) 
 
where v and C are the initial uptake rate and concentration of substrate, respectively.  All data 
were expressed as means ± S.E.M., and statistical analysis was performed by the use of Student’s 
t test with p < 0.05 as the criterion of significance. 
     The half-inhibitory concentration (IC50) value of inhibitor to ciprofloxacin uptake was 
calculated by the following equation (2), where % of control and I are observed % of control 
uptake, the inhibitor concentration used, respectively. 
 9
 
% of Control = IC50/(IC50+ I) × 100  (2) 
 
In situ intestinal closed loop experiment 
 
     Male Wistar rats (220 ± 20 g body weight) were housed three per cage with free access to 
commercial chow and tap water, and were maintained on a 12 h dark/light cycle in an 
air-controlled room (temperature, 24.0 ± 1°C; humidity, 55 ± 5%).  All animal experimentation 
was carried out in accordance with the guide of Tokyo University of Science’s Institutional 
Animal Care and Use Committee.  The permeability of rat intestinal membrane was evaluated 
by an in situ intestinal closed loop method.  Male Wistar rats fasted overnight were anesthetized 
with pentobarbital.  The abdominal cavity was opened and an intestinal loop (length: 10 cm) 
was made at the jejunum (2-12 cm form the ligament of Treitz) and ileum (2-12 cm from the 
caecum) by cannulation with silicone tubing (i.d., 3 mm).  The intestinal contents were removed 
by slow infusion of saline and air.  The test solution (phosphate-buffered solution, adjusted to 
pH 7.4) containing ciprofloxacin (10 M) in the absence or the presence of inhibitors was 
introduced into the intestinal loop and both ends of the loop were ligated.  For P-gp, Bcrp and 
Oatp inhibitor, ivermectin (10 M), 7,8-benzoflavone (10 M), naringin (500 M) was used, 
respectively.  After a certain period (usually 20 min), the luminal solution in the loop was 
collected.  The permeability of ciprofloxacin was evaluated in terms of the percentage of dose 
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absorbed, calculated by subtracting the remaining amount of ciprofloxacin from the administered 
amount.  The following equation (3) was used to calculate the apparent permeability (Papp): 
 
Papp = ka × V/2rl  (3) 
 
where ka is the first-order absorption rate constant of ciprofloxacin estimated from the percentage 
of the dose absorbed during the defined period, V is the volume of ciprofloxacin solution 
introduced to the loop, and r and l represent the radius and length of the used segment of intestine, 
respectively.  The length was 10 cm, and the values of the radius of each intestinal segment 
reported by Fagerholm et al. [34] were used (0.18 cm for jejunum and ileum). 
 
Preparation of the vascular perfused intestinal loop 
 
     A small intestinal loop (ileum, about 10 cm) was isolated from male Wistar rats (220 ± 20 g 
body weight) and its blood vessels were perfused as described [35].  Briefly, in addition with in 
situ closed loop study, the superior mesenteric artery and vein were cannulated with polyethylene 
tubes (i.d., 0.5 mm).  The cannulated intestinal segment was isolated from other portions and 
suspended in a serosal bath containing 100 mL of Krebs-Henseleit bicarbonate buffer solution 
(KHBB, 118 mM NaCl, 1.18 mM KCl, 1.18 mM KH2PO4, 1.27 mM CaCl2, 4.47 mM MgSO4, 
24.88 mM NaHCO3, and 10 mM glucose adjusted to pH 7.4 with NaOH) at 37oC.  Single-pass 
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perfusion of the blood vessel was started just after the intestine was isolated and continued 
throughout the experiment.  KHBB containing BSA (3%) was used as the vascular perfusate at a 
rate of 0.5 mL/min and was gassed with O2:CO2 = 95:5 before and during the transport 
experiments [36].  The vascular perfusate was collected at 0-5, 5-10, 10-15, and 15-20 min.  
The permeability of ciprofloxacin evaluated by disappearance from intestinal lumen and by 
absorbed amount in vascular perfusate was estimated following equation (3). 
 
Ussing-type chamber experiment 
 
     Rat intestinal tissue sheets were prepared as described previously [37].  Briefly, male 
Wistar rats (220 ± 20 g body weight) were anesthetized with pentobarbital and a segment of 
ileum was removed.  The tissue was rapidly stripped from serosal muscle layers, and mounted 
vertically in a Ussing-type chamber having an exposed area of 0.5 cm2.  The volume of bathing 
solution on each side was 5.0 mL, and the temperature was maintained at 37°C.  The transport 
buffer solution (125 mM NaCl, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM CaCl2, 1.2 mM MgSO4, 
25 mM glucose, and 25 mM HEPES adjusted to pH 7.4 with Tris) was gassed with O2:CO2 = 
95:5 before and during the experiments.  In the inhibition study, the inhibitors were added to 
both mucosal and serosal chambers.  Transport was estimated in terms of permeability 
coefficient (in unit of centimeter per minute), which was obtained by dividing the flux by the 
initial concentration of ciprofloxacin (10 M) on the donor side.  For inhibition study, 1, 3, 10, 
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30, 100 and 500 M of naringin was used.  The flux was obtained from the slope of the linear 




     The concentration of ciprofloxacin in all samples was quantified with an HPLC.  The 
HPLC system consisted of a constant-flow pump (PU-980; Japan Spectroscopic Co., Ltd., Tokyo, 
Japan), a fluorescence detector (FP-1520; Japan Spectroscopic Co., Ltd., Tokyo, Japan), 
integrator (807-IT; Japan Spectroscopic Co., Ltd., Tokyo, Japan), and an automatic sample 
injector (AS-950; Japan Spectroscopic Co., Ltd., Tokyo, Japan).  A TSK-gel ODS 80-Ts (C18. 
150 mm × 4.6 mm, 5 mm, Tosoh Co., Ltd., Tokyo, Japan) was used as the analytical column, and 
the mobile phase was composed of 30 mM sodium phosphate in water and acetonitrile.  The 
assay was linear over the concentration range used in the present study.  The calibration curve 
for ciprofloxacin was prepared in a concentration range from 5 nM to 100 nM.  The correlation 
coefficient was always better than 0.998.  The intra-day coefficient of variation (CV) and the 





Absorption of ciprofloxacin by in situ closed loop method 
 
     At first, rat in situ closed loop method using rat jejunum and ileum was performed in order 
to evaluate absorptive transporters of ciprofloxacin.  As shown in Fig. 1, the permeability of 
ciprofloxacin (10 M) in rat jejunum and ileum was 1.15 ± 0.143 × 10-5 cm/sec and 1.14 ± 0.154 
× 10-5 cm/sec, respectively.  The permeability in the presence of ivermectin (10 M), an 
inhibitor of P-gp, and 7,8-benzoflavone (10 M), an inhibitor of Bcrp, was increased to 1.41 ± 
0.03 × 10-5 cm/sec in jejunum and 2.28 ± 0.02 × 10-5 cm/sec in ileum.  When an OATP inhibitor 
naringin was added in the presence of ivermectin or 7,8-benzoflavone, the permeability was 
significantly decreased to 0.650 ± 0.28 × 10-5 cm/sec in jejunum and 0.603 ± 0.16 × 10-5 cm/sec 
in ileum, respectively. 
 
Absorption of ciprofloxacin by vascular perfusion method 
 
     Papp of ciprofloxacin in rat ileum was measured with or without vascular perfusion by 
means of closed loop method to confirm the absence of nonspecific effect of vascular perfusion 
on the intestinal permeability.  The permeability of ciprofloxacin (10 M) in rat ileum without 
and with vascular perfusion was 1.14 ± 0.15 × 10-5 cm/sec and 1.20 ± 0.30 × 10-5 cm/sec, 
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respectively (Table 1).  Because no significant difference was observed in Papp between both 
conditions in all conditions, it was confirmed that vascular perfusion caused no effect on the 
intestinal permeability of ciprofloxacin during the experimental period.  As shown in Fig. 2, 
cumulative amount of ciprofloxacin appeared in the vascular lumen after addition to intestinal 
lumen was increased 1.7-fold from 302 ± 55.7 pmol/20 min to 518 ± 95.0 pmol/20 min in the 
presence of 7,8-benzoflavone (10 M) and ivermectin (10 M) in perfusate.  Addition of 
naringin (500 M) with ivermectin and 7,8-benzoflavone, the cumulative amounts of 
ciprofloxacin significantly decreased to 139 ± 43.3 pmol/20 min. 
 
Intestinal permeability of ciprofloxacin by Ussing-type chamber method 
 
     To characterize the naringin sensitive portion of ciprofloxacin absorption, effect of naringin 
on permeation of ciprofloxacin was studied by the Ussing-type chamber method.  The 
permeation of ciprofloxacin (10 M) in the serosal-to-mucosal direction was higher than that in 
the opposite direction (Fig. 3).  Naringin reduced the mucosal-to-serosal permeation of 
ciprofloxacin with an IC50 value of 7.48 ± 1.94 M (Fig. 4).  Such reduction of permeation of 
ciprofloxacin was observed only in the direction from apical to serosal permeation but not in 
serosal-to-mucosal permeation (Fig. 3). 
 
Characterization of ciprofloxacin uptake by Xenopus laevis oocytes expressing Oatp1a5 
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     To clarify whether ciprofloxacin is a substrate for Oatp1a5 and to investigate inhibitory 
effect of naringin on Oatp1a5-mediated uptake of ciprofloxacin, the uptake of ciprofloxacin by 
Xenopus laevis oocytes expressing Oatp1a5 was examined.  The time course of ciprofloxacin 
uptake by oocytes injected with Oatp1a5 cRNA or water is shown in Fig. 5A.  The uptake of 
ciprofloxacin by Oatpt1a5-expressing oocytes was significantly higher than that by water-injected 
oocytes (p < 0.05).  Since the Oatp1a5-specific uptake of ciprofloxacin increased linearly up to 
30 min, the initial uptake rate was evaluated as an index of uptake in the following studies.  Fig. 
5B shows the concentration dependence of the Oatp1a5-mediated ciprofloxacin uptake.  The Km 
and Vmax values were 136 ± 21.8 M and 31.1 ± 1.80 pmol/oocyte/30 min, respectively.  The 
uptake of ciprofloxacin by Oatp1a5-expressing oocytes was not changed from pH 5.0 to 7.0 (Fig. 
6).  Naringin inhibited the Oatp1a5-mediated uptake of ciprofloxacin with IC50 value of 17.8 ± 
7.64 M (Fig. 7). 
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Discussion and Conclusion 
 
   Fluoroquinolones are efficiently absorbed from small intestines despite their hydrophilicity, 
implying an involvement of carrier-mediated transport in their absorption process.  We have 
already demonstrated that several fluoroquinolones are transported by OATP1A2, which is one of 
human OATP molecules expressed in Caco-2 cells [8].  Accordingly, we hypothesized that 
OATP is responsible for the intestinal absorption of fluoroquinolones and in the present study, we 
examined intestinal absorption of ciprofloxacin, as a model compound of fluoroquinolones, in 
rats by means of in vitro and in situ experimental techniques, especially focusing on rat Oatp1a5, 
since it was shown to be expressed at the apical membrane of rat intestinal epithelial cells [29]. 
   In this study, naringin was selected as an inhibitor for Oatp1a5, because it was reported to 
inhibit OATP/Oatp-mediated transport of talinolol, pravastatin and pitavastatin [14-18].  
However, recent investigations have shown that naringin has a significant inhibitory effect on not 
only Oatp1a5 but also P-gp and Bcrp [14,15,20,28,38,39].  Since ciprofloxacin is a substrate of 
P-gp and Bcrp [4,5,7,37,40], ivermectin (an inhibitor of P-gp) [41] and 7,8-benzoflavone (an 
inhibitor of Bcrp) [39] were simultaneously used with naringin in order to evaluate absorptive 
transport of ciprofloxacin.  Meanwhile, ivermectin (10 M) and 7,8-benzoflavone (10 M) did 
not inhibit [3H]estrone-3-sulfate uptake by oocytes expressing Oatp1a5, indicating that both 
ivermectin and 7,8-benzoflavone do not affect Oatp1a5-mediated transport at the present 
condition (data not shown).   
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   To clarify the impact of influx transporters in intestinal absorption of ciprofloxacin, rat 
intestinal permeability of ciprofloxacin was measured by the in situ closed loop method (Fig. 1).  
In the presence of ivermectin and 7,8-benzoflavone, the permeability with naringin was decreased 
by 70% of that in the absence of naringin, suggesting that influx transporters susceptible to 
naringin are significantly involved in intestinal absorption process of ciprofloxacin.  In addition, 
this phenomenon was also observed in vascular perfused study combined with in situ closed loop 
method (Fig. 2), demonstrating that inhibitory effect of naringin on intestinal influx transporter 
decreases in vivo plasma concentration of ciprofloxacin.  The permeability obtained by absorbed 
ciprofloxacin into vascular vessels was lower than that by disappeared ciprofloxacin form small 
intestine (table 1).  The permeability by disappeared ciprofloxacin from small intestine involve 
absorbed, adsorbed and metabolized amount in epithelial cells.  Taki et al. [36] showed that 
60-80% of Metkephamid was eliminated from rat upper jejunum, while absorbed amount of 
Metkephamid was only 0.3-1.2%.   They discussed that these differences may be caused by 
well-metabolized characteristics of Metkephamid in rat upper jejunum.   But, considering that 
ciprofloxacin is relatively stable [42], the differences may be caused by basolateral transport in 
rat ileum.  In addition to in vitro study (Fig. 5), these findings imply that Oatp1a5 at least 
contributes to the intestinal absorption of ciprofloxacin in rats. However, efflux transporters such 
as P-gp and Bcrp may decrease ciprofloxacin transport from being absorbed simultaneously. 
   Because Km value of 136 M (Fig. 5) in the Oatp1a5-mediated transport of ciprofloxacin is 
close to solubility limit of ciprofloxacin, approximately 500 M, Oatp1a5 is considered to 
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function effectively in rat intestinal absorption of ciprofloxacin.  In order to prove the 
involvement of Oatp1a5 in intestinal absorption of ciprofloxacin, Ussing-type chamber method 
using rat ileum is performed (Figs. 3 and 4).  Because secretary transport of ciprofloxacin was 
not inhibited by 500 M of naringin on Fig. 3, we consider that this ciprofloxacin transport by 
P-gp and Bcrp is not inhibited by the bellow 500 M of naringin.  So, we carried out the Ussing 
Chamber without ivermectin and 7,8-benzoflavone.  Naringin reduced the absorptive 
permeation of ciprofloxacin, with IC50 value of 7.48 M (Fig. 4).  This value involves more than 
apical uptake.  Assuming that the absorptive permeation is depending on apical uptake, the 
value is comparable to the IC50 value of 17.8 M obtained by oocytes expressing Oatp1a5 (Figs. 
4 and 7).  Because similar IC50 values were reported in Oatp1a5-mediated transport of talinolol 
(12.7 M) and pravastatin (30.4 M) by Oatp1a5-expressing oocytes, this accordance suggested 
that Oatp1a5 contributes to the intestinal permeation of ciprofloxacin [14,16].  However, we are 
unable to rule out a possibility of an involvement of other influx transporters such as Oatp2b1 in 
the ciprofloxacin absorption, while the localization of Oatp2b1 in the intestinal epithelial cells has 
yet to be determined [30,32].  Our previous data suggested that Oatp1a5-mediated transport of 
estrone 3-sulfate, Compound A and pravastatin observed pH-dependency [13,16].  But that of 
ciprofloxacin did not represent pH-dependency.  Our previous data suggested that OATP1A2 
mediated uptake of levofloxacin was not observed pH dependency, but that of tebipenem pivoxil 
was observed pH-dependency [8,43].  pH-dependency by OATP/Oatp transport may be 
dependent on substrate. 
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     Decreased amounts of ciprofloxacin permeability by naringin represent absorptive 
transporters expression of ciprofloxacin such as Oatp1a5, suggesting that the expression of the 
transporters in ileum is higher than that in jejunum.  Since it is reported that Oatp1a5 expression 
is higher in lower part of small intestine than in upper part of the small intestine [29,44], this may 
also support the involvement of Oatp1a5 in intestinal absorption of ciprofloxacin. 
   On the other hand, both OATP1A2 and OATP2B1 are expressed at apical membranes of 
human intestinal epithelial cells [11,19].  Interestingly, expression level of OATP2B1 was 
reported to be much higher than that of OATP1A2 in human small intestine [45].  Imanaga et al. 
[26] demonstrated that OATP2B1-mediated absorption of fexofenadine is subject to the genotype 
of OATP2B1 c.1457C>T and apple juice in human clinical study.  Therefore, 
OATP2B1-mediated transport may substantially contribute to intestinal absorption of drugs in 
human.  Neuhofel et al. [27] reported that oral bioavailability of ciprofloxacin with orange juice 
was decreased compared to water.  Several investigations have indicated that 
OATP/Oatp-mediated absorption of drugs is a putative site of drug-fruit juice interactions [25,46].  
Since orange juice contains OATP/Oatp inhibitors such as naringin and hesperidine, observed 
ciprofloxacin-orange juice interaction supports that ciprofloxacin is absorbed by OATP 
transporter [20,47]. 
     In conclusion, the present study demonstrates that Oatp1a5 has several roles in the 
intestinal absorption of ciprofloxacin in rats, although other influx and/or efflux transporters may 
not be excluded for intestinal absorption of ciprofloxacin.  Because most of fluoroquinolones are 
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efficiently absorbed from small intestines and show relatively high bioavailability, our present 
study suggests that OATP/Oatp at least contributes to intestinal absorptive process of 
fluoroquinolones.  Furthermore, our findings should be useful to predict drug-fruit juice 
interaction in the intestinal absorption process. 
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Table 1 
   Disappeared and absorptive permeability of ciprofloxacin in various conditions 
Drug medium in situ closed Loop Vascular perfused loop (disappeared) 
Vascular perfused 
loop (absorbed) 
CPFX (10 M) 1.14 ± 0.154 1.20 ± 0.304 0.334 ± 0.0511 
+ ivermectin (10 M) 
+ 7,8-benzoflavone (10 M) 2.28 ± 0.227
† 1.89 ± 0.195† 0.535 ± 0.0979 
+ ivermectin (10 M) 
+ 7,8-benzoflavone (10 M) 
+ naringin (500 M) 
0.655 ± 0.248* 1.07 ± 0.130* 0.106 ± 0.0477* 
All data are presented as mean ± S.E.M. (n=3-5). † and * indicates a significant difference from 
the permeability of ciprofloxacin without any inhibitors and with ivermectin and 









Fig. 1.  Effect of Inhibitors of Oatps, P-gp and Bcrp on Ciprofloxacin Disappearance from 
Rat Jejunum and Ileum by In Situ Loop Method. 
     Intestinal Permeability of 10 M ciprofloxacin was obtained by disappearance from rat 
ileum loop at pH 7.4 and 37oC.  Closed and open bars represent permeability of 10 
ciprofloxacin without and with 10 M ivermectin and 10 M 7,8-benzoflavone, respectively.  
Dotted bars represent permeability of ciprofloxacin with 500 M naringin in addition to 10 M 
ivermectin and 10 M 7,8-benzoflavone.  Each result represents the mean ± S.E.M.  (n=3-6).  
† and * indicates a significant difference from the permeability of ciprofloxacin without any 
inhibitors and with ivermectin and 7,8-benzoflavone. 
 
Fig. 2.  Absorption of Ciprofloxacin by In Vitro Loop Method with Vascular Perfusion in 
Rat Ileum. 
     Absorbed amount was calculated from the recovered amount of ciprofloxacin in vascular 
outflow sample at pH 7.4 and 37oC.  Closed and open circles represent 10  ciprofloxacin 
without and with 10 M ivermectin and 10 M 7,8-benzoflavone.  Triangles represent absorbed 
amount of ciprofloxacin with 500 M naringin in addition to 10 M ivermectin and 10 M 
7,8-benzoflavone.  Each result represents the mean ± S.E.M.  (n=3-6).  * indicates a 




Fig. 3.  Effect of Naringin on Absorptive and Secretory Transports of Ciprofloxacin by 
Ussing-type Chamber Method in Rat Ileum. 
     Mucosal-to-serosal and serosal-to-mucosal permeation of 10 M ciprofloxacin was 
calculated from sample in receiver-side by Ussing-type chamber method in rat ileum at pH 7.4 
and 37oC.  Circle and triangle symbols represent transported ciprofloxacin without and with 500 
M naringin, respectively.  Open and closed symbols represent serosal-to-mucosal and 
mucosal-to-serosal transport of ciprofloxacin, respectively.  Each result represents the mean ± 
S.E.M.  (n=3-5) and * indicates a significant differences from mucosal-to-serosal transport of 
ciprofloxacin in the absence of naringin. 
 
Fig. 4.  Concentration Dependent Effect Naringin on Absorptive Permeability of 
Ciprofloxacin by Ussing-type Chamber Method in Rat Ileum. 
     Mucosal-to-serosal transport of ciprofloxacin was measured in the presence of 1-500 M 
naringin at pH 7.4 and 37oC.  Each result represents the mean ± S.E.M.  (n=3-6). 
 
Fig. 5.  Characterization of Uptake of Ciprofloxacin by Oatp1a5 Expressing Oocytes. 
     Uptake of 20 M ciprofloxacin by Xenopus oocytes injected with cRNA of Oatp1a5 or 
water was measured at pH 7.4 and room temperature.  (A) Time-dependence of uptake of 
 31
ciprofloxacin by Oatp1a5 expressing oocytes was performed.  Closed and open circles represent 
Oatp1a5-expressing and water-injected oocytes, respectively.  Uptakes are expressed as 
cell-to-medium ratio.  Each result represents the mean ± S.E.M.  (n=10-13) and * indicates a 
significant difference from the uptake by water-injected oocytes (p < 0.05).  (B) 
Concentration-dependent uptake of ciprofloxacin by Oatp1a5 expressing oocytes was performed.  
Uptake of ciprofloxacin was measured for 30 min at pH 7.4 and room temperature.  Oatp1a5 
mediated uptake was obtained by subtraction of the uptake by water-injected oocytes from these 
by Oatp1a5-expressing oocytes.  Concentrations of ciprofloxacin are 5, 20, 50, 200, and 500 M.  
Each result represents the mean ± S.E.M.  (n=4-8). 
 
Fig. 6.  pH-Dependency of Ciprofloxacin Uptake by Oatp1a5 Expressing Oocytes. 
     Uptake of 20 M ciprofloxacin by Xenopus oocytes injected with cRNA of rat Oatp1a5 or 
water was measured for 30 min at pH 5.0, 6.0 and 7.0, and room temperature.  Closed and open 
circles represent Oatp1a5-expressing and water-injected oocytes, respectively.  Uptakes are 
expressed as cell-to-medium ratio.  Each result represents the mean ± S.E.M. (n=6-10). 
 
Fig. 7.  Concentration Dependent Effect of Naringin on Ciprofloxacin Uptake by Oatp1a5 
Expressing Oocytes. 
     Uptake of 20 M ciprofloxacin by Xenopus oocytes injected with cRNA of rat Oatp1a5 or 
water was measured for 30 min at pH 7.4 and room temperature.  Results are shown as 
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percentage of control uptake measured in the absence of naringin after subtracting the uptake by 
water-injected oocytes from that by rat Oatp1a5 cRNA-injected oocytes.  Concentrations of 
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